The drug is buprenorphine, and as of January 12, 2023, any doctor with a standard DEA Schedule III registration can prescribe it — no special waiver, no extra certification, no arbitrary cap on how many patients they can treat. That single policy change, driven by the Mainstreaming Addiction Treatment Act tucked into the December 2022 omnibus spending bill, dismantled one of the most criticized barriers in American medicine. For the estimated millions of people struggling with opioid use disorder, including a disproportionate number of older adults managing chronic pain, the path to evidence-based treatment now runs through the same office where they get their blood pressure checked.
But access on paper and access in practice are proving to be very different things. A University of Michigan study published in 2024 found that despite the easier prescribing rules, overall buprenorphine use has changed remarkably little — the anticipated national surge simply did not materialize. For families navigating dementia care, where opioid misuse among aging patients and their overwhelmed caregivers is a quiet crisis, understanding what buprenorphine is, how to actually obtain it, and why so many pharmacies still refuse to carry it matters more than the policy headlines suggest. This article walks through all of it: the rule change, who is prescribing, what it costs, and the real-world obstacles that persist.
Table of Contents
- What Is the Opioid Addiction Drug Patients Can Now Get From Their Regular Doctor?
- Why Hasn’t Buprenorphine Prescribing Surged Despite Easier Rules?
- Emergency Departments and the New Front Door to Treatment
- How Telehealth Has Changed Buprenorphine Access in 2025
- The Pharmacy Problem — Why Finding Buprenorphine Is Still Difficult
- What Buprenorphine Costs and How to Pay for It
- Where Buprenorphine Access Goes From Here
- Conclusion
- Frequently Asked Questions
What Is the Opioid Addiction Drug Patients Can Now Get From Their Regular Doctor?
Buprenorphine is a partial opioid agonist, meaning it activates the same brain receptors as drugs like oxycodone or heroin but produces a far weaker effect — enough to ease withdrawal symptoms and reduce cravings without delivering the dangerous euphoria that drives addiction. It has been FDA-approved for treating opioid use disorder since 2002, but for two decades, doctors who wanted to prescribe it had to jump through a bureaucratic gauntlet known as the X-waiver system. That system required special training, a separate DEA registration number, and imposed strict limits on how many patients a single provider could treat — initially just 30, later raised to 100 or 275 depending on the practitioner’s qualifications. The elimination of the X-waiver changed the math entirely. Now primary care physicians, psychiatrists, nurse practitioners, and physician assistants can all prescribe buprenorphine under their existing DEA license.
There are no longer any federal patient caps. A family doctor in rural Iowa who sees three patients with opioid use disorder can prescribe for all three without filing additional paperwork, just as a geriatric specialist managing an older adult’s post-surgical opioid dependence can fold buprenorphine into a standard treatment plan. The only new federal requirement: as of June 27, 2023, practitioners must complete an eight-hour training on opioid use disorder treatment when they apply for or renew their DEA registration. For dementia caregivers, this is particularly relevant. Older adults with cognitive decline are at elevated risk for opioid misuse — they may forget they already took a dose, or a well-meaning caregiver may inadvertently overprescribe pain medication. Having the regular doctor who already understands the patient’s cognitive status be able to prescribe buprenorphine directly, rather than referring out to a specialized addiction clinic, removes a logistical barrier that many families of dementia patients simply cannot manage.
Why Hasn’t Buprenorphine Prescribing Surged Despite Easier Rules?
The numbers tell a complicated story. Buprenorphine prescriptions have increased 83 percent over the past decade, which sounds encouraging until you notice that the growth has plateaued in recent years — meaning most of that increase predates the X-waiver elimination. The 2024 University of Michigan study confirmed what many addiction medicine specialists feared: removing the regulatory barrier did not automatically translate into more doctors writing prescriptions. Stigma, lack of confidence in managing addiction, and concerns about diversion still weigh heavily on practitioners who have never treated opioid use disorder before. There is, however, a notable shift in who is doing the prescribing. Nurse practitioners and physician assistants surpassed primary care doctors as the dominant prescribers of buprenorphine after 2021.
This trend has continued and may actually be the more significant development for patients, particularly those in underserved or rural areas where physician shortages are severe. If your loved one’s primary care provider is a nurse practitioner at a community health center, that NP is now statistically more likely to be comfortable prescribing buprenorphine than a physician in private practice. The limitation worth understanding: even when a provider is willing to prescribe, many lack the infrastructure to support ongoing addiction treatment. Buprenorphine works best as part of a comprehensive plan that includes counseling and monitoring. A busy primary care office seeing 25 patients a day may write the prescription but have no capacity to provide or coordinate the wraparound care that makes treatment stick. For families managing dementia alongside a loved one’s opioid dependence, this means the prescription alone, while valuable, is not the whole answer.
Emergency Departments and the New Front Door to Treatment
One of the most promising developments has been in emergency rooms. Emergency department buprenorphine prescribing rose from just 2 percent of opioid use disorder encounters in 2019 to 8 percent in 2023. That fourfold increase matters because emergency departments are often where opioid crises become visible — an overdose, a fall caused by intoxication, or a confused elderly patient brought in by a frightened family member. Starting buprenorphine in the ER, sometimes called “bridge prescribing,” can stabilize a patient long enough to connect them with outpatient care. Consider a scenario that geriatric ER doctors see regularly: a 72-year-old with mild cognitive impairment arrives after a fall at home.
The workup reveals she has been taking far more oxycodone than prescribed, partly because she cannot reliably remember her dosing schedule. Before 2023, the ER physician could treat the fall but had limited options for addressing the opioid problem unless they happened to hold an X-waiver. Now, that same physician can prescribe a short course of buprenorphine, contact her primary care doctor, and set up a treatment handoff — all within a single ER visit. The growth in ER prescribing also reflects a cultural shift within emergency medicine. The American College of Emergency Physicians actively supported the X-waiver elimination and has been vocal about integrating addiction treatment into standard emergency care. For dementia caregivers who end up in the ER during a crisis, knowing that buprenorphine can be initiated on the spot — and that you can ask about it — is genuinely useful information.
How Telehealth Has Changed Buprenorphine Access in 2025
The DEA finalized permanent telemedicine rules effective December 31, 2025, and for many patients, this may turn out to be more consequential than the X-waiver elimination itself. Under the new rules, patients can receive buprenorphine prescriptions via telehealth — including audio-only phone calls, not just video visits. An initial prescription of up to a six-month supply can be issued without any in-person visit at all. After that, a face-to-face appointment is required before further prescriptions. The audio-only provision is particularly significant for older adults and their caregivers. Many dementia patients and their aging spouses are not comfortable with video calls, may lack reliable internet, or live in areas where broadband access is poor.
A phone call with a doctor who can then electronically send a buprenorphine prescription to a pharmacy removes multiple barriers at once — transportation, technology literacy, and the sheer time burden of getting a cognitively impaired person to a clinic appointment. Compare this to the pre-2023 reality, where a patient might need to travel hours to see one of the limited number of X-waivered providers, sit in a waiting room, and then return for regular follow-ups just to maintain their prescription. The tradeoff is real, though. Telehealth-initiated buprenorphine treatment means the prescribing doctor has not physically examined the patient or observed their behavior in person. For older adults with cognitive decline, subtle signs of overmedication or drug interactions can be easy to miss on a phone call. Caregivers who pursue the telehealth route should be prepared to serve as the doctor’s eyes and ears — reporting changes in behavior, alertness, or balance that the patient themselves may not recognize or communicate.
The Pharmacy Problem — Why Finding Buprenorphine Is Still Difficult
Getting a prescription is only half the battle. A September 2025 study from the USC Schaeffer Center found that roughly 40 percent of major chain pharmacies — including Walmart, CVS, and Rite Aid locations — choose not to stock buprenorphine at all. The reasons are a tangle of stigma, regulatory caution, and business decisions. Pharmacies worry about attracting what they perceive as difficult clientele, about DEA scrutiny of their controlled substance dispensing numbers, and about the administrative burden of managing a medication that still carries heavy cultural baggage despite being a frontline medical treatment. The disparities are stark and follow predictable lines. Pharmacies in predominantly Black neighborhoods stock buprenorphine at a rate of just 18 percent.
In predominantly Latino neighborhoods, the figure is 17 percent. In white neighborhoods, it jumps to 46 percent. For families already navigating the labyrinth of dementia care — which itself disproportionately affects Black and Latino communities — adding a medication access barrier rooted in racial geography compounds an already unfair burden. What this means in practice: if your loved one’s doctor prescribes buprenorphine, call the pharmacy before you drive there. Ask specifically whether they carry sublingual buprenorphine tablets or films. If the nearest pharmacy does not stock it, ask the prescribing doctor’s office for help identifying one that does, or check whether a mail-order pharmacy option is available through the patient’s insurance plan. Do not assume that a prescription written means a prescription filled — that assumption has left too many patients in unnecessary withdrawal.
What Buprenorphine Costs and How to Pay for It
Cost varies dramatically depending on the formulation. Generic buprenorphine sublingual tablets run between $45 and $130 per month with discount coupons — manageable for many families, though not trivial on a fixed income. Brand-name Suboxone film costs $400 to $600 per month, a price point that is difficult to justify when generics are clinically equivalent for most patients. At the high end, Sublocade, a once-monthly injection administered in a clinic, runs $1,500 to $1,900 per month but eliminates the daily compliance challenge entirely — a meaningful advantage for patients with cognitive impairment who cannot reliably self-administer a daily medication.
Most insurance plans and Medicaid cover generic buprenorphine, though prior authorization is commonly required, which can delay treatment initiation by days or weeks. Medicaid coverage has been a particular bright spot: states that expanded Medicaid under the Affordable Care Act saw buprenorphine prescribing increase by 27.3 percent, while non-expansion states experienced a 2.1 percent decline. If your family member has Medicaid in an expansion state, the financial path to treatment is considerably smoother. In non-expansion states, patient assistance programs from manufacturers and nonprofit organizations may help fill the gap, but they require paperwork and patience that caregivers of dementia patients rarely have in surplus.
Where Buprenorphine Access Goes From Here
The infrastructure for broader buprenorphine access now exists in a way it never has before — the legal barriers are down, telehealth rules are permanent, and the medication itself is off-patent and available in generic form. What remains stubbornly resistant to policy change is the human element: physician reluctance, pharmacy gatekeeping, and a public that still largely views addiction treatment medications with suspicion rather than as the routine medical tools they are. For the dementia care community specifically, the next frontier is integration.
As the population ages and the overlap between chronic pain management, cognitive decline, and opioid dependence grows, geriatric care models will need to treat buprenorphine prescribing as a normal part of the toolkit — no different from prescribing a cholinesterase inhibitor for memory or an antihypertensive for blood pressure. The regulatory path is now clear. The clinical path is catching up. The cultural path, as always, will take the longest.
Conclusion
Buprenorphine is the most effective medication available for opioid use disorder, and since January 2023, any doctor, nurse practitioner, or physician assistant with a standard DEA registration can prescribe it without special waivers or patient caps. Permanent telehealth rules finalized at the end of 2025 go further, allowing patients to start treatment with a simple phone call and receive up to six months of medication before needing an in-person visit. For families managing dementia care alongside opioid dependence — a more common intersection than most people realize — these changes remove real barriers. But the barriers that remain are not trivial.
Forty percent of major chain pharmacies do not stock the medication. Racial disparities in pharmacy access persist. Many willing prescribers lack the support infrastructure to provide comprehensive addiction care. And the anticipated surge in prescribing following the X-waiver elimination has not materialized, suggesting that policy alone cannot overcome decades of stigma. If buprenorphine is relevant to someone in your care, the most practical steps are straightforward: talk to their regular doctor, confirm pharmacy availability before filling the prescription, explore telehealth options if transportation is a barrier, and check insurance coverage for generic formulations early in the process.
Frequently Asked Questions
Can my parent’s regular doctor really prescribe buprenorphine now?
Yes. As of January 12, 2023, any practitioner with a standard DEA Schedule III registration — including primary care doctors, psychiatrists, nurse practitioners, and physician assistants — can prescribe buprenorphine for opioid use disorder. No special waiver is needed, and there are no federal limits on how many patients a provider can treat.
Does my family member need to see the doctor in person to start buprenorphine?
Not necessarily. Under permanent DEA telemedicine rules effective December 31, 2025, patients can receive an initial buprenorphine prescription via telehealth, including audio-only phone calls, with up to a six-month supply. An in-person visit is required before further prescriptions beyond that initial period.
What if the pharmacy does not carry buprenorphine?
This is a common problem. A 2025 USC Schaeffer Center study found that about 40 percent of major chain pharmacies do not stock it. Always call the pharmacy before going. Ask the prescribing doctor for alternative pharmacy recommendations, or explore mail-order options through the patient’s insurance.
Is buprenorphine safe for older adults with dementia?
Buprenorphine can be used in older adults, but it requires careful monitoring, especially in patients with cognitive impairment who may not reliably self-administer daily doses or report side effects. The monthly Sublocade injection eliminates daily dosing concerns but costs significantly more. Any decision should involve the patient’s primary care doctor and, ideally, a geriatric specialist.
How much does buprenorphine cost without insurance?
Generic sublingual tablets cost roughly $45 to $130 per month with discount coupons. Brand-name Suboxone film runs $400 to $600 monthly. The Sublocade monthly injection costs $1,500 to $1,900. Most insurance and Medicaid plans cover the generic, though prior authorization may be required.
Has buprenorphine prescribing actually increased since the X-waiver was removed?
Not as much as expected. While prescriptions grew 83 percent over the past decade overall, growth has plateaued in recent years. A 2024 University of Michigan study found that the policy change did not produce a significant national increase in use, likely due to persistent provider stigma and lack of clinical infrastructure.
